Celgene, Acceleron Complete Enrollment in Studies

Biopharmaceutical companies Celgene and Acceleron Pharma Inc. (XLRN) said Thursday they have completed enrollment in the phase 3 studies of luspatercept in patients with myelodysplastic syndromes and beta-thalassemia.

The companies, which have a global collaboration deal, said they expect to report top-line results from the clinical trials in the middle of 2018. Luspatercept is being developed to treat a range of hematologic diseases including MDS, beta-thalassemia, and myelofibrosis, Shares of Celgene are up 0.4% in pre-market trading, while shares of Acceleron are unchanged.

By Kristen Tardella